Six-year_experience_with_a_comprehensive_approach_to_the_treatment_of_recurrent_childhood_acute_lymphoblastic_leukemia_(ALL-REZ_BFM_85)._A_relapse_study_of_the_BFM_group._Between_April_1985_and_March_1987_130_children_and_adolescents_up_to_18_years_of_age_with_first_relapse_of_acute_lymphoblastic_leukemia_(ALL)_were_registered_on_the_stratified_and_randomized_multicentric_trial_ALL-REZ_BFM_85_designed_for_patients_pretreated_with_intensive_front-line_therapies._Stratification_criteria_were_time_and_site_of_relapse:_bone_marrow_(BM)_relapse_on_or_up_to_6_months_after_stopping_front-line_therapy_(group_A),_BM_relapse_beyond_6_months_after_therapy_(group_B),_and_isolated_extramedullary_relapse_at_any_time_(group_C)._Treatment_consisted_of_alternating_courses_of_polychemotherapy_including_randomly_administered_high-_or_intermediate-dose_methotrexate_(HDMTX:12_g/m2_as_4-hour_infusion;_IDMTX:_1_g/m2_as_36-hour_infusion)._During_maintenance_therapy_the_patients_received_daily_oral_thioguanine_and_biweekly_intravenous_(IV)_MTX._The_overall_second_complete_remission_(CR)_rate_was_92%_(groups_A,_B,_and_C:_88%,_92%,_and_100%),_and_the_probability_of_event-free_survival_(EFS)_at_6_years_is_0.31_+/-_0.04_(groups_A,_B,_and_C:_0.18_+/-_0.05,_0.30_+/-_0.07,_and_0.72_+/-_0.11)._HDMTX_did_not_prove_to_be_superior_to_IDMTX,_which_led_to_premature_stopping_of_randomization._Risk_factor_analyses_showed_early_relapse,_particularly_BM_relapse_within_18_months,_and_T-cell_phenotype_to_be_independent_predictors_of_poor_outcome._The_incidence_of_central_nervous_system_(CNS)_relapses_following_BM_relapse_was_19%,_indicating_that_reprophylaxis_to_the_CNS_with_IV/intrathecal_(IT)_MTX_was_insufficient._For_17_children_who_received_bone_marrow_transplantation_in_second_CR_from_HLA-compatible_siblings_the_EFS_was_0.53_+/-_0.12_at_5_years._Their_outcome_was_not_influenced_by_the_above-mentioned_risk_factors._With_the_proposed_treatment_regimen_long-lasting_second_remissions_can_be_achieved_in_about_one_third_of_patients_even_after_intensive_front-line_treatment.